Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | F11 | P03951 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20913213 | 0.93 | LPL (0.43) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL16382778 | 0.86 | CA1 (0.49) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL28334985 | 0.86 | LPL (0.54) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL24467420 | 0.86 | LPL (0.54) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL20424266 | 0.85 | LPL (0.46) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL20911819 | 0.83 | LPL (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL22604529 | 0.83 | LPL (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL25330900 | 0.82 | LIPG (0.44) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL25330897 | 0.82 | LIPG (0.44) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL29530408 | 0.82 | LIPG (0.44) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2888006-B1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES USEFUL AS AMPK ACTIVATORS | MERCK SHARP & DOHME (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-2888005-B1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME (US) | 2019-04-03 | — | — | EP | disclosed |
| US-9382243-B2 | Azabenzimidazole tetrahydropyran derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382243-B2 | Azabenzimidazole tetrahydropyran derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382243-B2 | Azabenzimidazole tetrahydropyran derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9290517-B2 | Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290517-B2 | Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150284411-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[E,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME LLC | 2015-10-08 | — | — | US | disclosed |
| US-20150284411-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[E,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME LLC | 2015-10-08 | — | — | US | disclosed |
| US-20150210685-A1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES | MERCK SHARP & DOHME LLC | 2015-07-30 | — | — | US | disclosed |
| US-20150210685-A1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES | MERCK SHARP & DOHME LLC | 2015-07-30 | — | — | US | disclosed |
| US-20150210685-A1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES | MERCK SHARP & DOHME LLC | 2015-07-30 | — | — | US | disclosed |
| WO-2014031465-A1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284411-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[E,2-B]FURAN DERIVATIVES | PRKAG2, PRKAB2, PRKAG1 | LPL 450/4885LIPG 279/4885CA1 4885/4885 |
| US-20150210685-A1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES | PRKAG2, PRKAB2, PRKAG1 | LPL 708/4885LIPG 415/4885CA1 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.